Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Techno Drugs's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Techno Drugs Total Assets Related Terms
Techno Drugs Total Assets Historical Data
* Premium members only.
The historical data trend for Techno Drugs's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Techno Drugs's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs (DHA:TECHNODRUG) has a Total Assets of BDT7,637 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Techno Drugs and its competitors.
Is Techno Drugs' Total Assets too high?
Techno Drugs' current Total Assets is BDT7,637 Mil. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' Total Assets compare to ZTS and UTHR?
Techno Drugs' Total Assets of BDT7,637 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Techno Drugs and its competitors. Techno Drugs's current Total Assets is BDT7,637 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current Total Assets of BDT7,637 Mil. The current Total Assets is BDT7,637 Mil. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current Total Assets is BDT7,637 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
